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Abstract 
 
In the bone tissue engineering field, there is a growing interest in the application of bioactive glass scaffolds 
(45S5 Bioglass®) due to their bone bonding ability, osteoconductivity and osteoinductivity. However, such 
scaffolds still lack some of the required functionalities to enable the successful formation of new bone, e.g. 
effective antibacterial properties. A large number of studies suggest that selenium (Se) has significant role in 
antioxidant protection, enhanced immune surveillance and modulation of cell proliferation. Selenium 
nanoparticles (SeNp) have also been reported to possess antibacterial as well as antiviral activities. In this 
investigation, uniform, stable, amorphous SeNp have been synthesized and additionally immobilized within 
spherical PLGA particles (PLGA/SeNp). These particles were used to coat bioactive glass-based scaffolds 
synthesized by the foam replica method. Samples were characterized by X-ray diffraction (XRD), Fourier 
transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), energy dispersive X-ray 
spectroscopy (EDS) and transmission electron microscopy (TEM). SeNp, 45S5Bioglass®/SeNp and 
45S5Bioglass®/PLGA/SeNp showed a considerable antibacterial activity against Gram positive bacteria, 
Staphylococcus aureus and Staphylococcus epidermidis, one of the main causative agents of orthopedic 
infections. The functionalized Se-coated bioactive glass scaffolds represent a new family of bioactive, 
antibacterial scaffolds for bone tissue engineering applications. 
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1. Introduction 
Bone tissue is the major structural and supportive connective tissue composed of about 25% water, 25% 
protein i.e. collagen fibers, and 50% mineral salts of which the most calcium and phosphorous salts. It is a 
dynamic, highly vascularised tissue with the major role to provide structural support for the body [1]. The 
worldwide incidence of bone disorders and conditions significantly increases recently and it is expected to 
double by 2020 [2]. The field of bone tissue engineering was initiated a few decades ago and is based on the 
understanding of bone structure, bone mechanics, and tissue formation [1, 2]. Bone tissue engineering aims to 
successfully regenerate or repair bone and applies methods from materials engineering and life sciences to 
produce artificial or natural constructs [3, 4]. There are several approaches for the regeneration or for the 
formation of the new tissue. One is to isolate specific cells from a patient and to grow them on a three-
dimensional scaffold after which the construct will be delivered to the desired site in the patient’s body 
aiming to direct new tissue formation into the scaffold [3]. Another way is to implant scaffold for tissue 
ingrowth directly in vivo to stimulate and to direct tissue formation in situ [3-5]. Biomaterials for scaffolds 
preparation have to possess certain physical, chemical, and biological properties [6-8]. However, it is difficult 
for any biomaterial to satisfy all of the requirements which led to the development of wide variety of 
composites or hybrid materials. These hybrid materials are made by combination of two or more biomaterials, 
with enhanced functionalities, in the form of polymer–polymer blends, organic-inorganic hybrids and 
polymer–ceramic composites [3, 9-12]. Recently, there is a growing interest in the application of bioactive 
silicate glasses due to their bone bonding ability and osteoconductivity [13, 14]. In addition, these highly 
surface reactive materials exhibit osteogenic and angiogenic effects [13]. Structural 3D bioactive glass 
scaffolds with suitable interpenetrating porosity and mechanical stability have been developed in recent years 
[14-16]. However such scaffolds still lack some of the required functionalities to enable the successful 
formation of new vascularized bone in critical size bone defects, e.g. enhanced bioactivity by incorporation of 
bioactive molecules or growth factors and effective antibacterial properties. Additionally, the angiogenic and 
antibacterial characteristics of scaffolds are now being examined in more detail, the goal being to integrate 
these functions in a bioactive scaffold with osteoconductive and osteoinductive properties [3, 17-21]. 
Biodegradable and bioresorbable polymers such as polylactide (PLA), polyglycolide (PGA), 
poly(lactide-co-glycolide) (PLGA), poly (epsilon-caprolactone) (PCL) are approved by the World Health 
Organization and Food and Drug Administration and are very often used as materials in medicine and 
pharmacy as polymeric prodrugs, for drug delivery or therapeutic systems [22, 23]. They have numerous 
advantages, such as excellent processing characteristics, degradation rates that can be tailored for the intended 
application, as well as exhibiting unique pharmacokinetics and pharmacological efficacy [23]. PLGA micro 
and nanoparticles are used for the controlled delivery of several classes of medicaments such as anticancer 
agents, growth factors, antibiotics, antimicrobial agents, etc [24]. Metal and metalloid nanoparticles are used 
in various biomedical applications. For example, silver, gold and platinum are some of the alternative 
inorganic materials with antimicrobial properties [25]. Selenium nanoparticles have also been reported to 
possess antibacterial as well as antiviral activities [26]. Additionally, several findings suggest that selenium 
plays critical roles in a variety of physiological processes and selenium intake may be necessary for bone 
health [26]. In a recent review, Zeng et al have summarized current knowledge of the effects of selenium on 
bone and the underlying mechanisms [27]. Selenium deficiency can retard growth and alter bone metabolism 
[27-29]. Insufficient selenium intakes have been associated with increased risk to bone disease [29].  
The main idea of this work was to design and evaluate a new bioactive material for bone tissue 
engineering applications, combining bioactive glass (BG) scaffolds and selenium nanoparticles (SeNp), or 
poly(lactide-co-glycolide) particles with immobilized selenium nanoparticles (PLGA/SeNp) applied as 
coatings on the BG scaffolds. 3D BG scaffolds were fabricated by the foam replica technique [15]. The 
samples were characterized by X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), 
scanning electron microscopy (SEM), energy dispersive X-ray spectroscopy (EDS) and transmission electron 
microscopy (TEM). The antibacterial activity of the samples was determined against Gram positive bacteria: 
Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 1228), Bacillus subtilis (ATCC 
6633), and Gram negative: Klebsiella pneumoniae (ATCC 13883). 
The present scaffold development corresponds to a growing family of bioactive glass-based scaffolds 
incorporating antibacterial, functional coatings [12, 30-34] although combination of SeNp and BG has not 
been investigated previously.  
 
2. Materials and Methods 
2.1. Materials  
For the scaffold fabrication, 45S5 Bioglass® powder with a composition: 45 SiO2, 24.5 CaO, 24.5 Na2O, 6 
P2O5 in wt%, was used. Fully hydrolyzed PVA (Mw approx. 30000) (Merck, Darmstadt, Germany) was used 
to prepare the Bioglass® slurries to make scaffolds. Polyurethane (PU) foam (Eurofoam Deutschland GmbH) 
with 60ppi (pores per inch) was used as a template to fabricate scaffolds by the foam replica method 
described elsewhere [15].  
Poly(D,L-lactide-co-glycolide) (PLGA) was obtained from Durect, Lactel, Adsorbable Polymers 
International and had lactide to glycolide ratio of 50:50. Molecular weight of polymer was 40000-50000g/mol. 
Polyvinyl pyrrolidone (povidone, PVP) was obtained from Merck Chemicals Ltd (k-25, Merck, Germany). 
For the preparing SeNp, sodium selenite (Na2SeO3) as well as bovine serum albumin (BSA) were obtained 
from Sigma-Aldrich, St Louis, MO. Ascorbic acid was purchased from Microvit, Adisseo, USA (C6H8O6, 
176.13 g/mol). All other chemicals and solvents were of reagent grade.  
 
2.2. Methods 
2.2.1. Synthesis of bioactive glass scaffolds 
BG scaffolds were prepared by the foam replica method according to the process introduced earlier [15]. 
Briefly, glass powder was dispersed in the solution of polyvinyl alcohol (PVA) in deionized water and under 
constant stirring. In such obtained slurry, PU foams were immersed so that the foam struts were coated with 
glass particles. PU foam was used as template in this replication method and it was cut into 20 x 10 x 10 mm3 
samples. After drying at room temperature, the as-coated foams were slowly burned out in order to minimize 
damage to the glass coating and then the glass network (scaffold) was sintered by heat treatment at 1100 °C 
[15]. 
 
2.2.2. Synthesis of selenium nanoparticles (SeNp) 
In the synthesis of SeNp, firstly 217 mg of ascorbic acid have been dissolved in 10mL distilled water and 
afterward 12.5mL of 0.02M sodium selenite was added into the solvent mixture. The formation of selenium 
nanoparticles was immediately visualized by a color change of the reactant solution from the colorless to 
orange. Simultaneously with the addition of sodium selenite, 5 mL of BSA was dropwise added into the 
solution to stabilize particles i.e. to form BSA-capped SeNp. 
 
2.2.3. Synthesis of PLGA particles with immobilized selenium nanoparticles (PLGA/SeNp) 
PLGA/SeNp microspheres were produced using a physicochemical solvent/nonsolvent method. First of all, 
SeNp were prepared as described above. Afterward, PLGA commercial granules (220 mg) were dissolved in 
20 ml acetone over approximately 2 h at room temperature.Then, the solution containing SeNp (0.5ml) was 
added to a solution of PLGA in acetone, continuously being homogenized at 21000rpm during 15min, with 
the resulting solution becoming slightly orange. PLGA/SeNp precipitated by the addition of ethanol (60ml) 
and the solution became whitish. Thus obtained solution was very slowly poured into 40ml of aqueous PVP 
solution (0.5 % w/w) while continuously stirring at 500rpm by a stirrer. Using PVP as the stabiliser, negative 
charged PLGA/SeNp particles are produced, i.e. with specific zeta potential, which prevents their 
agglomeration. Zeta potential of the PLGA/SeNp was measured by Zetasizer Nano ZS particle analyzer 
(Model ZEN3600, Malvern Instruments, Malvern, UK) and it was determined to be -30.1±0.5mV. 
 
2.2.4. Coating of 45S5Bioglass® scaffolds by SeNp or by PLGA/SeNp 
Sintered 45S5 Bioglass scaffolds were coated with SeNp or with PLGA/SeNp (Figure 1). The coating was 
performed by simple soaking/immersing the scaffolds into solution containing SeNp or into solution 
containing PLGA/SeNp microspheres. This was done with the help of a copper wire gently entwined in the 
pores of the scaffold. The scaffolds were immersed during the 5min while continuously stirring at 100rpm. 
The coated scaffolds were left to dry at room temperature and ambient pressure. Weight percentage of coating 
on BG scaffolds was determined by thermo-gravimetric analysis from room temperature to 1000 °C (SETSYS 
Evo TG-DTA/DSC, Seteram Instrumentation, Lyon France), with heating rate of 10 °C/min. Precise data was 
obtained by recording TG curves of uncoated BG scaffolds, SeNp, PLGA and PLGA/SeNp, as well as BG 
scaffolds coated with SeNp and PLGA/SeNp. Coating of SeNp on BG scaffolds was estimated to be 2.5 wt%, 
while coating of PLGA/SeNp on BG scaffold was 1.18 wt%. Loading of SeNp in PLGA was 0.15wt%. 
 
Figure 1. Schematic diagram showing the steps involved in the coating of 45S5Bioglass® by SeNp or by 
PLGA/SeNp 
 2.3. Characterization 
2.3.1. X-ray diffraction 
For X-ray diffraction analysis, the samples were firstly grinded and powdered. For identification of the phase 
composition (phase analysis) of the uncoated scaffolds or scaffolds coated by SeNp or by PLGA/SeNp, X-ray 
diffraction was used, with a Philips PW 1050 diffractometer with Cu-Kα1,2 radiation (Ni filter). The 
measurements were carried out in the 2θ range of 10° to 70°, with a scanning step width of 0.05°, and 2 s per 
step. 
 
2.3.2. Fourier-transform infrared spectroscopy (FTIR) 
The quality analysis of the 45S5Bioglass® scaffolds coated by SeNp or by PLGA/SeNp was further 
performed with FTIR spectroscopy. FTIR spectra of the samples were recorded in the range of 400-4000cm-1 
using a Nicolet™ iS™50 FT-IR Spectrometer. FTIR measurements of the samples were carried out to 
identify the possible interactions between the surface of the BG scaffolds and SeNp or interactions between 
BG and PLGA/SeNp. 
 
2.3.3. Scanning electron microscopy (SEM) 
To analyze the microstructures of the 45S5Bioglass® scaffolds coated by SeNp or by PLGA/SeNp, scanning 
electron microscopy (SEM) was carried out, on a JEOL-JSM-6610LV instrument. The samples for SEM 
analysis were coated with gold using the physical vapour deposition (PVD) process. Samples were covered 
with gold (Leica SCD005 sputter coater), using 30mA current from the distance of 50mm during 180s. The 
gold coating was used to prevent their charging.  
 
2.3.4. Energy dispersive spectroscopy (EDS) 
Energy dispersive spectroscopy (EDS) (model: X-Max Large Area Analytical Silicon Drift connected with 
INCA Energy 350 Microanalysis System) was used for the elemental characterization of 
45S5Bioglass®/SeNp and 45S5Bioglass®/PLGA/SeNp scaffolds.  
 
2.3.5. Transmission electron microscopy (TEM) 
Transmission electron microscopy using a JEOL JEM-1400plus instrument provided further morphological 
characterization of the SeNp incoporated within the PLGA particle, based on the exploration of the individual 
microstructures. 
 
2.3.6. Antibacterial activity 
 
The antibacterial activities of the tested compounds were investigated against Gram positive bacteria: 
Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 1228), Bacillus subtilis (ATCC 
6633), and Gram negative: Klebsiella pneumoniae (ATCC 13883). A broth microdilution method was used to 
determine minimum inhibitory concentrations (MICs) of samples. MIC represents the lowest concentration of 
a compound at which the microorganism does not demonstrate visible growth. MICs were determined 
according to Clinical and Laboratory Standards Institute (CLSI 2005) [35]. Tests were performed in Müller 
Hinton broth. Overnight broth cultures were prepared for each strain, and the final concentration in each well 
was adjusted to 2 ×106 CFU/ml. Uncoated 45S5Bioglass® scaffolds as well as 45S5Bioglass® scaffolds 
coated by SeNp or by PLGA/SeNp were crushed into powder and then a serial doubling dilutions in 1% 
dimethylsulfoxide were prepared. A serial doubling dilution of the compounds were prepared in Müller–
Hinton broth, in a 96-well microtiter plate, over the range of 1000-12.5 g/ml. In the tests, 0.05% triphenyl 
tetrazolium chloride (TTC, Aldrich Chemical Company Inc., USA) was also added to the culture medium as a 
growth indicator. As a positive control of growth, wells containing only the microorganisms in the broth were 
used. Bacteria growth was determined after 24 h of incubation at 37 °C. All of the MIC determinations were 
performed in duplicate, and two positive growth controls were included.  
 
3. Results and discussion  
X-ray diffractograms of samples (commercial BSA used in the synthesis for capping SeNp (given here just 
for comparison purposes), SeNp, PLGA/SeNp, uncoated 45S5Bioglass® scaffolds, 45S5Bioglass® scaffolds 
coated by SeNp and 45S5Bioglass® scaffolds coated by PLGA/SeNp) are shown in Figure 2.  
P2O5, Na2O, CaO and SiO2 are the main components of 45S5Bioglass®. The ratio between them is very 
important considering bioactive character of the material. 45S5 Bioglass is glass where 45 is the wt. 
percentage of SiO2 and 5 is the molar ratio of Ca to P. Depending on the thermal treatment, bioactive glass 
powders exhibit different degrees of crystallinity [15, 36]. The narrow peaks with high intensity indicate high 
degree of crystallinity of 45S5Bioglass® scaffold (Figure 2). PLGA, as well as SeNp, did not exhibit any 
crystalline peaks because of their amorphous nature (Figure 2). The only difference between X-ray 
diffraction patterns of uncoated 45S5Bioglass®, 45S5Bioglass®/SeNp, and 45S5Bioglass®/PLGA/SeNp 
scaffolds is in peak which belongs to BSA which is used in the synthesis of SeNp as a capping agent. X-ray 
diffraction patterns of uncoated 45S5Bioglass® as well as 45S5Bioglass®/SeNp scaffolds, and 
45S5Bioglass®/PLGA/SeNp scaffolds showed only two phases, both belonging to the family of combeites (c) 
(Figure 2) [37]. These phases are low- (Na4.2Ca2.8(Si6O18)) and high-combeite (Na15.78Ca3(Si6O12)) [37]. From 
the literature is known that 45S5 Bioglass® has a higher index of bioactivity than hydroxyapatite [38] and 
bioactivity has been shown to be reduced but not suppressed by crystallization of the phase Na2Ca2Si3O9, as 
found by Clupper and Hench, which showed amorphous calcium phosphate formation on its surface when it 
was contacted with simulated body fluid (SBF) [39]. The other crystalline phases, namely Na4Ca4Si6O18 also 
exhibits bioactivity because of its similarity to the phase Na2Ca2Si3O9 [36, 37]. Na4Ca4Si6O18 and 
Na15Ca3.84Si12O36 phases can be considered as forerunner phases for low- (Na4.2Ca2.8(Si6O18) and high-
combeite (Na15.78Ca3(Si6O12)), respectively [37] meaning that 45S5Bioglass®/SeNp, and 
45S5Bioglass®/PLGA/SeNp scaffolds are also bioactive. 
 
Figure 2. X-ray diffraction patterns of commercial BSA used in the synthesis for capping SeNp, as-prepared 
SeNp, PLGA/SeNp, uncoated 45S5Bioglass®, 45S5Bioglass®/SeNp and 45S5Bioglass®/PLGA/SeNp.The c 
stands for combeite. 
 
The FTIR spectra of the 45S5Bioglass®/SeNp and 45S5Bioglass®/PLGA/SeNp samples are shown in Figure 
3. FTIR spectroscopy of these samples was performed to ascertain the presence of SeNp or PLGA/SeNp on 
the scaffolds. As observed, both spectra reveal bands at 3292 cm−1, 2654 cm−1, 1056 cm−1, 1036 cm−1, 940 
cm−1, 701cm−1, 616 cm−1 and 524 cm−1. The broad band at 3292 cm−1 is attributed to OH− absorption. The 
band at 1036 cm−1 is associated with P-O vibrational mode [40, 41] while the band at 940 cm−1 is attributed to 
CH2 out-of-plane wag [42]. In the spectra of 45S5Bioglass®/PLGA/SeNp the band at 1744 cm−1 is associated 
with C=O group and 1581 cm−1 and 1456 cm−1 are associated with C-H group (in CH3 and -CH2) [42]. In the 
spectra of 45S5Bioglass®/SeNp the band at 1580 cm−1 corresponds to the NH2 deformation (amide II band) 
[42]. Apart from those peaks, no other peaks can be identified. 
 
Figure 3. FTIR spectra of 45S5Bioglass®/SeNp and 45S5Bioglass®/PLGA/SeNp scaffolds. 
 
The microstructures of the prepared 45S5Bioglass®/SeNp scaffolds were examined by SEM (Figure 4). The 
images were taken from the interior section of the scaffolds. A highly porous structure and tailored pore shape 
for specific application, i.e. bone defects, are essential requirements for ideal bone scaffolds. From these SEM 
images it can be seen that 45S5Bioglass®/SeNp scaffolds have a well interconnected porous structure. The 
pore size of the scaffold is around 500m (Figure 4). At higher magnification on the strut microstructures of 
a 45S5Bioglass®/SeNp scaffold, it is visible that the strut is coated by SeNp. SeNp particles on the strut are 
spherical, fairly uniform and agglomerated. 
 
 
Figure 4. SEM images showing typical (A) pore (bars 1mm and 500m) and (B) strut microstructures (bars 
1m) of a 45S5Bioglass® scaffold coated by SeNp. These are representative images of the scaffold cross-
sections. 
 
Figure 5 shows a SEM micrograph of a SeNp-coated 45S5Bioglass® scaffold, with EDS results on a selected 
area of the sample. A surface elemental composition analysis of the SeNp-coated 45S5Bioglass® scaffold 
showed a strong selenium atom signal, along with silicon, calcium, sodium, oxygen, phosphorus and carbon. 
In the spectra, there are also peaks which belong to gold and this is due to the preparation of the samples for 
SEM and EDS measurements, i.e. the samples were coated with gold using the physical vapour deposition 
process. No obvious peaks for other elements or impurities were observed in the spectra. These results further 
confirm the successful coating of 45S5Bioglass® scaffold with SeNp. 
 
   
 
  
 
  
Figure 5. SEM image showing the surface of SeNp-coated 45S5Bioglass® scaffold, with EDS results on a 
selected areas of the sample. 
 
Representative SEM images of 45S5Bioglass®/PLGA/SeNp scaffolds are given in Figure 6. These SEM 
images show typical pore and struts microstructures of a 45S5Bioglass® scaffold coated by PLGA/SeNp. 
From these images, it can be seen that in the case of 45S5Bioglass®/PLGA/SeNp scaffolds pores are less 
uniform compared to 45S5Bioglass®/SeNp scaffolds. PLGA/SeNp particles are spherical in shape and with 
sizes around 1 m or less. It is apparent that in both cases the coatings reduce the porosity of scaffolds 
however given the large size of pores in the as-fabricated scaffolds, the coated samples still exhibit a suitable 
pore structure (not quantified in this study). Figure 6 shows also a TEM image of PLGA/SeNp particle from a 
45S5Bioglass® scaffold strut showing heterogeneously distributed SeNp within the PLGA polymer matrix. 
SeNp particles are spherical-shaped. 
 Figure 6 Representative SEM images (A) of 45S5Bioglass®/PLGA/SeNp scaffolds showing typical pore 
(bars 500m) and strut (bar 10m) microstructures of a 45S5Bioglass® scaffold coated by PLGA/SeNp. TEM 
image (B) of PLGA/SeNp particle from 45S5Bioglass® strut showing heterogeneously distributed SeNp 
within the PLGA polymer matrix (bar 500nm). 
 
Energy dispersive spectroscopy was also used for the surface elemental composition analysis of the 
45S5Bioglass® scaffold coated with PLGA/SeNp. The EDS spectra showed that the main elements of the 
45S5Bioglass®/PLGA/SeNp scaffolds are carbon, oxygen, calcium, sodium and silicon (Figure 7). Peaks 
which belong to selenium are also present in the spectra. Peaks of gold were from the sputter coated layer. No 
peaks for other elements or impurities were observed in the spectra. The EDS analysis of the PLGA/SeNp 
coated 45S5Bioglass® scaffold showed a much more intense presence of carbon and oxygen compared to 
45S5Bioglass®/SeNp scaffold (Figure 5) thus indicating the coating of scaffold by PLGA/SeNp. 
 
 
 
 
 
Figure 7. SEM image showing the surface of 
45S5Bioglass®/PLGA/SeNp scaffold, with EDS 
results on selected areas of the sample. 
 
 
 
 
 
The antimicrobial activity of the samples SeNp, 45S5Bioglass®/SeNp, 45S5Bioglass®/PLGA/SeNp and 
uncoated 45S5Bioglass® scaffolds was examined. Minimal inhibitory concentrations of samples were 
determined using a broth microdilution assay against Gram positive bacteria: Staphylococcus aureus (ATCC 
25923), Staphylococcus epidermidis (ATCC 1228), Bacillus subtilis (ATCC 6633), and Gram negative: 
Klebsiella pneumoniae (ATCC 13883 (Figure 8).  
Hospital-acquired infections (nosocomial infections-not present nor incubating at admission) are caused by 
bacteria and other pathogens and the most common of these infections are infections associated with 
orthopedic devices and surgical implants. Infections that are associated with a variety of surgical implants 
have clinical and economic consequences and often result in serious disabilities [43]. Staphylococcus is a 
group of bacteria and, while Staphylococcus epidermidis is not usually pathogenic, Staphylococcus aureus is 
considered to be the most dangerous in this group. It can cause a number of diseases and infections range 
from mild to life threatening. However, even Staphylococcus epidermidis, such as Bacillus subtilis, could 
cause serious infections in patients with compromised immune systems. The gram-negative bacteria, 
Klebsiella pneumoniae also may colonize sites when the host defenses are compromised and cause a variety 
of lung, bone, heart and bloodstream infections [44]. All of them may be highly resistant to traditional 
antibiotic therapies [25, 45]. 
From the literature is known that selenium nanoparticles are very important for bone health [27, 28] but also 
could serve as antibacterial agent. The role of SeNp as antibacterial agent has been supported in several recent 
studies [26, 46, 47]. 
Results of this study (Figure 8) provided the evidence of a considerable antibacterial activity against 
Staphylococcus aureus (ATCC 25923) and Staphylococcus epidermidis (ATCC 1228), in the presence of 
SeNp as well as in the presence of samples 45S5Bioglass®/SeNp and 45S5Bioglass®/PLGA/SeNp. SeNps 
also inhibited growth of Bacillus subtilis and Klebsiella pneumoniae. 
In the literature, several mechanisms by which nanoparticles may exhibit antimicrobial activity have been 
proposed [48, 49]. Nanoparticles may express better antimicrobial activity compared to conventional 
preparations due to their large surface-to-mass ratio, better penetration through the cell membrane to affect 
the intracellular processes from the inside, surface charge, etc. A better understanding of the antibacterial 
activity of SeNp would require a proper investigation of the membrane-bound and intracellular nanoparticles. 
 
  
Figure 8. Antibacterial activity of SeNp, 45S5Bioglass®/SeNp, 45S5Bioglass®/PLGA/SeNp and uncoated 
45S5Bioglass®. Minimal inhibitory concentrations of samples were determined using a broth microdilution 
assay against Gram positive bacteria: Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis 
(ATCC 1228), Bacillus subtilis (ATCC 6633), and Gram negative: Klebsiella pneumoniae (ATCC 13883). 
The data are presented as mean values of two independent experiments (each with three replicates) ± SD. 
 
4. Conclusion  
45S5 Bioglass®-based scaffolds have been synthesized by the foam replica method and additionally coated 
by SeNp or by PLGA with immobilized SeNp. The coating of BG scaffolds by spherical, amorphous SeNp or 
by PLGA/SeNp microspheres was confirmed by XRD, FTIR, SEM and EDS analyses. SeNp, 
45S5Bioglass®/SeNp and 45S5Bioglass®/PLGA/SeNp scaffolds showed a considerable antibacterial activity 
against Gram positive bacteria Staphylococcus aureus and Staphylococcus epidermidis, one of the main 
causative agents of orthopedic infections. Our data suggest that 45S5Bioglass®/SeNp and 
45S5Bioglass®/PLGA/SeNp scaffolds are promising candidates for applications in the bone tissue 
engineering field since it is expected that such scaffolds coated by SeNp or coated by PLGA with 
immobilized SeNp will exhibit a combination of desirable properties in one device, i.e. controlled drug-
delivery function, promotion of bone regeneration and elimination of possible inflammatory responses or 
infections. Future studies will consider investigating the cell biology response to these scaffolds and in-vivo 
studies. 
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